BioNTech WKN: A2PSR2 ISIN: US09075V1026 Forum: Aktien Thema: Hauptdiskussion

Mehr kann maan nicht tun

Ja abwarten und Tee trinken ist angesagt

😄

Deswegen bekommt der noch morgen eine chance

Loony, Geduld nur etwas Geduld 😀

Ja heute wars wenigstens besser als gestern...

Da liefert BionTech die klar besseren Ergebnisse

Kurs wird grade durch 2 10k order in dem aktuellen Bereich fixiert

Onvista App ist auch gut

Auszug aus moderna fda Zusammenfassung 8.3 Known Risks The vaccine elicited increased local and systemic adverse reactions as compared to those in the placebo arm, usually lasting a few days. The most common solicited adverse reactions were pain at injection site (91.6%), fatigue (68.5%), headache (63.0%), muscle pain (59.6%), joint pain (44.8%), and chills (43.4%). Adverse reactions characterized as reactogenicity were generally mild to moderate; 0.2% to 9.7% of these events were reported as severe, with severe solicited adverse reactions being more frequent after dose 2 than after dose 1 and generally less frequent in older adults (≥65 years of age) as compared to younger participants. Among reported unsolicited adverse events, lymphadenopathy occurred much more frequently in the vaccine group than the placebo group and is plausibly related to vaccination. The number of participants reporting hypersensitivity-related adverse events was numerically higher in the vaccine group compared with the placebo group (258 events in 233 participants [1.5%] vs. 185 events in 166 participants [1.1%]). There were no anaphylactic or severe hypersensitivity reactions with close temporal relation to the vaccine. Serious adverse events, while uncommon (1.0% in both treatment groups), represented medical events that occur in the general population at similar frequency as observed in the study. Of the 7 SAEs in the mRNA-1273 group that were considered as related by the investigator, FDA considered 3 as related: intractable nausea and vomiting (n=1), facial swelling (n=2). For the serious adverse events of rheumatoid arthritis, peripheral edema/dyspnea with exertion, and autonomic dysfunction, a possibility of vaccine contribution cannot be excluded. For the event of B-cell lymphoma, an alternative etiology is more likely. An SAE of Bell’s palsy occurred in a vaccine recipient, for which a causal relationship to vaccination cannot be concluded at this time. No specific safety concerns were identified in subgroup analyses by age, race, ethnicity, medical comorbidities, or prior SARS-CoV-2 infection

Ladet euch Guidants herunter. Kurs in Echtzeit auf App. Und hört auf über Kurse von 100€ oder höher zu fabulieren. Aktuell bei 90,2€

Auszug aus fda BionTech Zusammenfassung 6.3. Known Risks The vaccine has been shown to elicit increased local and systemic adverse reactions as compared to those in the placebo arm, usually lasting a few days. The most common solicited adverse reactions were injection site reactions (84.1%), fatigue (62.9%), headache (55.1%), muscle pain (38.3%), chills (31.9%), joint pain (23.6%), fever (14.2%). Adverse reactions characterized as reactogenicity were generally mild to moderate. The number of subjects reporting hypersensitivity-related adverse events was numerically higher in the vaccine group compared with the placebo group (137 [0.63%] vs. 111 [0.51%]). Severe adverse reactions occurred in 0.0-4.6% of participants, were more frequent after Dose 2 than after Dose 1 and were generally less frequent in older adults (>55 years of age) (

Sehe ich auch so, langfristig ein enormes Potential, vl ein neue aktie die wirklich lange im depot bleibt

Ich habe nicht viel Erfahrung aber ich glaube nicht dass die Aktie nochmal hoch gehen wird. Zumindest nicht so Hoch, dass ich meine Verluste verkraften könnte

Aussitzen ist die Devise. Auf gute news, wie nachbestellung der EU hoffen. Zulassungen haben anscheinend keinen wirklichen Effekt mehr

Kauft euch jetzt wieder ein. Wieso soll so eine Aktie jetzt den bach runter gehen. ?? Alles spricht für die Aktie grad